Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Surrogate Endpoints Don't Convince ODAC: Panel Votes No On Two Centocor/Ortho Biotech Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

ODAC votes 14-1 against Yondelis in combination with Doxil for ovarian cancer, and 13-0 against Doxil in combination with docetaxel for metastatic breast cancer.

You may also be interested in...



Keeping Track: Four Novel Agents Clear FDA; Two Complete Response Letters Issued

The latest drug development news and highlights from our FDA Performance Tracker.

Oncology Has Different Risk Management Standards, FDA’s Pazdur Acknowledges

Risk mitigation in the oncology setting is unique, largely because of the different benefit/risk ratio, but also because the therapeutic area has "a de facto restricted distribution system," as FDA Office of Oncology Drug Products Director Richard Pazdur put it.

Oncology Has Different Risk Management Standards, FDA’s Pazdur Acknowledges

Risk mitigation in the oncology setting is unique, largely because of the different benefit/risk ratio, but also because the therapeutic area has "a de facto restricted distribution system," as FDA Office of Oncology Drug Products Director Richard Pazdur put it.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS069703

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel